Insider Buying: ADMA Biologics (NASDAQ:ADMA) Director Buys 7,000 Shares of Stock

ADMA Biologics Inc (NASDAQ:ADMA) Director Steve Elms bought 7,000 shares of the business’s stock in a transaction dated Thursday, March 5th. The shares were acquired at an average cost of $15.67 per share, for a total transaction of $109,690.00. Following the purchase, the director owned 2,038,730 shares of the company’s stock, valued at approximately $31,946,899.10. The trade was a 0.34% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

ADMA Biologics Price Performance

ADMA remained flat at $15.39 during trading hours on Monday. The company had a trading volume of 658,964 shares, compared to its average volume of 2,737,747. The company’s 50-day moving average price is $16.92 and its 200-day moving average price is $16.77. The firm has a market capitalization of $3.67 billion, a price-to-earnings ratio of 25.65 and a beta of 0.51. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.71 and a quick ratio of 3.74. ADMA Biologics Inc has a one year low of $13.76 and a one year high of $25.67.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.20. The business had revenue of $139.16 million for the quarter, compared to analyst estimates of $139.80 million. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The business’s revenue was up 18.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.46 earnings per share. Equities analysts predict that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have issued reports on ADMA. Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a research report on Tuesday, December 23rd. Wall Street Zen raised shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. Finally, Zacks Research upgraded ADMA Biologics from a “hold” rating to a “strong-buy” rating in a report on Monday, March 2nd. Two investment analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $32.00.

Institutional Trading of ADMA Biologics

A number of hedge funds have recently added to or reduced their stakes in ADMA. Quadrant Capital Group LLC increased its position in ADMA Biologics by 3.9% during the 2nd quarter. Quadrant Capital Group LLC now owns 16,660 shares of the biotechnology company’s stock valued at $303,000 after purchasing an additional 629 shares during the period. Lido Advisors LLC boosted its stake in shares of ADMA Biologics by 3.8% during the fourth quarter. Lido Advisors LLC now owns 17,107 shares of the biotechnology company’s stock valued at $312,000 after purchasing an additional 629 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in ADMA Biologics by 11.7% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 6,063 shares of the biotechnology company’s stock valued at $117,000 after buying an additional 634 shares during the period. Cim LLC raised its stake in ADMA Biologics by 0.7% in the third quarter. Cim LLC now owns 91,486 shares of the biotechnology company’s stock worth $1,341,000 after buying an additional 665 shares in the last quarter. Finally, Smartleaf Asset Management LLC raised its stake in ADMA Biologics by 28.9% in the second quarter. Smartleaf Asset Management LLC now owns 3,118 shares of the biotechnology company’s stock worth $57,000 after buying an additional 700 shares in the last quarter. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.